Grant: Master's Award: Canada Graduate Scholarships
University of Ottawa
$17,500.00
Novel Transglutaminase Inhibitors as an Anti-Cancer Therapeutic in High Grade Serous Ovarian Carcinoma
FY 2018-19
Summary
Ovarian cancer is the most lethal gynecological cancer worldwide and has a 5-year survival rate of less than 40%. Women are usually diagnosed after their cancer has grown large and/or metastasized throughout the body. Many of these women’s tumours will develop resistance to their chemotherapy medication and stop responding to treatment.
Cancer biologists believe that chemotherapy often fails to completely rid patients of their cancer because of the presence of there exists cancer stem-like cells. Cancer stem cells can divide and repopulate a tumour. Currently used chemotherapies successfully kill quickly growing cancer cells, however, it will not affect slow-growing cancer cells, like cancer stem cells, as much. If as few as 100 cancer stem cells remain after surgery or chemotherapy treatments, a tumour can reform and metastasize.
To improve treatment option for patients diagnosed with chemo-resistant forms of ovarian cancer, new drugs that target these cancer stem cells must be developed. We propose that a new drug called NC9 that inhibits the protein Transglutaminase (TG2), will do just that. This protein, when at higher levels than normal in a cell, have been shown to help tumour cells divide, spread, invade and develop resistance to chemotherapy. Inhibiting this protein has also been shown to make chemo-resistant cancer cells sensitive to common anti-cancer drugs again. We will be examining whether a new TG2 inhibitor will improve carboplatin treatment effectiveness of ovarian cancer cell lines and whether it will reduce the ability of these cells to divide, invade, metastasize and to make new cancer stem cells. The NC9 inhibitor has the potential to improve chemo-resistant ovarian cancer treatment, reduce rates of cancer recurrence, and increase patient survival.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
411241
Name
Grondin Melanie A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Novel Transglutaminase Inhibitors as an Anti-Cancer Therapeutic in High Grade Serous Ovarian Carcinoma
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Chemotherapy; Drug Therapy; High Grade Serous; Ovarian Cancer; Small Molecule Inhibitor; Tissue Transglutaminase 2
Abstract
Ovarian cancer is the most lethal gynecological cancer worldwide and has a 5-year survival rate of less than 40%. Women are usually diagnosed after their cancer has grown large and/or metastasized throughout the body. Many of these women’s tumours will develop resistance to their chemotherapy medication and stop responding to treatment.
Cancer biologists believe that chemotherapy often fails to completely rid patients of their cancer because of the presence of there exists cancer stem-like cells. Cancer stem cells can divide and repopulate a tumour. Currently used chemotherapies successfully kill quickly growing cancer cells, however, it will not affect slow-growing cancer cells, like cancer stem cells, as much. If as few as 100 cancer stem cells remain after surgery or chemotherapy treatments, a tumour can reform and metastasize.
To improve treatment option for patients diagnosed with chemo-resistant forms of ovarian cancer, new drugs that target these cancer stem cells must be developed. We propose that a new drug called NC9 that inhibits the protein Transglutaminase (TG2), will do just that. This protein, when at higher levels than normal in a cell, have been shown to help tumour cells divide, spread, invade and develop resistance to chemotherapy. Inhibiting this protein has also been shown to make chemo-resistant cancer cells sensitive to common anti-cancer drugs again. We will be examining whether a new TG2 inhibitor will improve carboplatin treatment effectiveness of ovarian cancer cell lines and whether it will reduce the ability of these cells to divide, invade, metastasize and to make new cancer stem cells. The NC9 inhibitor has the potential to improve chemo-resistant ovarian cancer treatment, reduce rates of cancer recurrence, and increase patient survival.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Grondin, Melanie A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~